Clinical Trial Update: IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating an immuno-oncology combination as first-line treatment for soft tissue sarcomas; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angiosarcoma
• Desmoplastic Small Round Cell Tumor
• Fibrosarcoma
• Leiomyosarcoma
• Malignant Peripheral Nerve Sheath Tumor
• Pleomorphic Liposarcoma
• Soft Tissue Sarcoma

Snippet

Sponsor: Fudan University | Conditions: Soft Tissue Sarcomas, Angiosarcoma | Phase 2 | Status: RECRUITING